Vis enkel innførsel

dc.contributor.authorBrix, Ninna
dc.contributor.authorGlerup, Mia
dc.contributor.authorThiel, Steffen
dc.contributor.authorMistegaard, Clara Elbæk
dc.contributor.authorSkals, Regitze Gyldenholm
dc.contributor.authorBerntson, Lillemor
dc.contributor.authorFasth, Anders
dc.contributor.authorNielsen, Susan Mary
dc.contributor.authorNordal, Ellen Berit
dc.contributor.authorRygg, Marite
dc.contributor.authorHasle, Henrik
dc.contributor.authorAlbertsen, Birgitte Klug
dc.contributor.authorHerlin, Troels
dc.date.accessioned2022-02-09T12:32:17Z
dc.date.available2022-02-09T12:32:17Z
dc.date.issued2021-10-22
dc.description.abstractObjective: Distinction on clinical grounds between acute lymphoblastic leukaemia presenting with arthropathy (ALLarthropathy) and juvenile idiopathic arthritis (JIA) is difficult, as the clinical and paraclinical signs of leukaemia may be vague. The primary aim was to examine the use of lectin complement pathway proteins as markers to differentiate ALLarthropathy from JIA. The secondary aims were to compare the protein levels at baseline and follow-up in a paired number of children with ALL and to examine the correlation with haematology counts, erythrocyte sedimentation reaction (ESR), C-reactive protein (CRP), blasts, relapse and death. Study design: In this observational study, we measured M-ficolin, CL-K1 and MASP-3 in serum from children with ALL (n=151) and JIA (n=238) by time-resolved immunofluorometric assays. Logistic regression was used for predictions of ALL risk, considering the markers as the respective exposures. We performed internal validation using repeated '10-fold cross-validation' with 100 repetitions computing the area under the curve (AUC) as well as positive and negative predictive values in order to evaluate the predictive performance. Results: The level of M-ficolin was higher in JIA than ALLtotal and the ALLarthropathy subgroup. The M-ficolin level normalised after remission of ALL. M-ficolin could differentiate ALL from JIA with an AUC of 94% and positive predictive value (PPV) of 95%, exceeding CRP and haemoglobin. In a dichotomised predictive model with optimal cut-offs for M-ficolin, platelets and haemoglobin, AUC was 99% and PPV 98% in detecting ALL from JIA. Conclusion: M-ficolin is a valuable marker to differentiate the child with ALL from JIA.en_US
dc.identifier.citationBrix N, Glerup M, Thiel S, Mistegaard CE, Skals RG, Berntson L, Fasth A, Nielsen, Nordal E, Rygg M, Hasle H, Albertsen BK, Herlin T. M-ficolin: a valuable biomarker to identify leukaemia from juvenile idiopathic arthritis. Archives of Disease in Childhood. 2021en_US
dc.identifier.cristinIDFRIDAID 1997140
dc.identifier.doi10.1136/archdischild-2021-322114
dc.identifier.issn0003-9888
dc.identifier.issn1468-2044
dc.identifier.urihttps://hdl.handle.net/10037/23996
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.journalArchives of Disease in Childhood
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleM-ficolin: a valuable biomarker to identify leukaemia from juvenile idiopathic arthritisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel